Nanjing Vazyme Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	905.53	804.9	434.25	1,967	1,545	1,478
Trading Asset Securities	2,035	2,049	2,222	1,514	1,719	1,976
Cash & Short-Term Investments	2,940	2,854	2,656	3,481	3,264	3,454
Cash Growth	1.17%	7.45%	-23.69%	6.65%	-5.49%	239.50%
Accounts Receivable	471.63	460.05	483.61	351.93	839.62	322.32
Other Receivables	9.91	9.65	20.81	4.07	7.72	4.67
Receivables	481.54	469.7	504.42	356.01	847.35	326.99
Inventory	351.52	343.67	362.18	346.25	364.2	242.19
Prepaid Expenses	-	-	0.05	-	-	-
Other Current Assets	40.91	40.18	48.58	47.12	89.71	28.1
Total Current Assets	3,814	3,708	3,571	4,230	4,565	4,051
Property, Plant & Equipment	599.91	617.48	726.07	767.3	679.48	308.98
Long-Term Investments	75.86	79.96	54.83	47.3	22.31	18.48
Goodwill	130.49	130.49	130.49	130.49	130.49	-
Other Intangible Assets	83.53	86.63	95.19	101.24	49.7	16.65
Long-Term Accounts Receivable	-	-	0.15	-	-	-
Long-Term Deferred Tax Assets	174.12	166.62	146.04	106.51	67.12	24.87
Long-Term Deferred Charges	207.55	220.12	278.91	280.54	318.31	145
Other Long-Term Assets	15.4	19.06	45.51	82.53	172.69	42.25
Total Assets	5,101	5,028	5,049	5,746	6,005	4,607
Accounts Payable	75.16	91.59	90.4	146.82	318.78	118.76
Accrued Expenses	61.41	116.69	129.74	112.52	258.07	104.7
Short-Term Debt	858.43	686.68	551.32	1,134	272.21	-
Current Portion of Long-Term Debt	35.5	28.43	-	-	-	-
Current Portion of Leases	-	-	57.03	46.16	58.25	31.25
Current Income Taxes Payable	23.53	32.86	0.6	0.03	0.54	20.02
Current Unearned Revenue	58.73	72.14	54.87	55.92	214.55	95.03
Other Current Liabilities	13.01	13.46	19.36	24.09	31.67	17.5
Total Current Liabilities	1,126	1,042	903.33	1,520	1,154	387.26
Long-Term Leases	113.57	127.33	143.36	106.89	127.68	59.93
Long-Term Unearned Revenue	63.25	61.76	48.38	21.38	19.25	16.24
Long-Term Deferred Tax Liabilities	0.98	1.03	1.26	1.51	11.19	0.87
Other Long-Term Liabilities	4.66	4.75	8.72	67.6	80.92	15.52
Total Liabilities	1,308	1,237	1,105	1,717	1,393	479.83
Common Stock	397.73	397.73	402.13	400.01	400.01	400.01
Additional Paid-In Capital	2,341	2,339	2,512	2,442	2,429	2,422
Retained Earnings	1,067	1,063	1,139	1,209	1,780	1,305
Treasury Stock	-5.01	-3	-104.4	-20.01	-	-
Comprehensive Income & Other	-0.55	-0.63	-3.97	-1.72	-	-
Total Common Equity	3,800	3,796	3,945	4,029	4,609	4,127
Minority Interest	-7.08	-4.82	-1.63	-0.11	3.2	-
Shareholders' Equity	3,793	3,791	3,944	4,029	4,612	4,127
Total Liabilities & Equity	5,101	5,028	5,049	5,746	6,005	4,607
Total Debt	1,007	842.44	751.71	1,287	458.14	91.18
Net Cash (Debt)	1,933	2,012	1,905	2,194	2,806	3,362
Net Cash Growth	6.39%	5.62%	-13.19%	-21.81%	-16.56%	230.91%
Net Cash Per Share	4.55	4.84	5.26	5.57	7.03	9.27
Filing Date Shares Outstanding	418.17	669.06	397.82	397	400.01	400.01
Total Common Shares Outstanding	418.17	669.06	397.82	397	400.01	400.01
Working Capital	2,688	2,666	2,668	2,711	3,411	3,664
Book Value Per Share	9.09	5.67	9.92	10.15	11.52	10.32
Tangible Book Value	3,586	3,579	3,720	3,798	4,429	4,111
Tangible Book Value Per Share	8.57	5.35	9.35	9.57	11.07	10.28
Machinery	-	-	712.88	656.11	513.97	250.31
Construction In Progress	-	-	69.42	127.48	69.44	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.